23 - CKD 2 Anemia Flashcards
KDOQI
Definition for CKD Anemia
Hemoglobin (Hb)
Males
Hb < 13.5 g/dL
Females
Hb < 12 g/dL
S/Sx of CKD Anemia
TachyCardia
- *PALE
- **Conjuctiva / palms / nail beds
Decreased MENTAL ACUITY / neurological sx
Worsening of LVH
Systolic Murmor
Fatigue / Dizziness / SOB / Palpitations / Chest Pain
Pathogenesis
CKD Anemia
Decreased Survival of RBCs / Bleeding
Erythropoietin (EPO)
normocytic & normochromic
Acute / Chronic Inflammatory Conditions
SEVERE HYPERparathyroidism
Microlytic Anemia = Iron deficiency
Macrolytic Anemia = Folic acid / vitb12 deficiency
aluminum toxicity
ESA
Use in CKD Anemia
Erythropoiesis Stimulating Agents
- *Exogenous ESA** is needed because:
- *Kidney is NO LONGER forming EPO** to stimulate RBC production in bone marrow
Glycoproteins with same biologic fxn as EPO
Reduced need for TRANSFUSION
SC or IV injections
Weight Based Dosing
When can we Initiate ESA Therapy?
KDOQI CPG
To start ESA, have to be below:
Hb < 11-12 g/dL
Goal is:
11 - 12 g/dL, not >13
we do NOT want a quick rise, due to overshooting
rate of rise:
1-2 over 1 month
When can we Initiate ESA Therapy?
FDA
To start ESA, have to be below:
Hb < 10 g/dL
Goal Followed
Goal is:
< 11 g/dL
we do NOT want a quick rise, due to overshooting
rate of rise:
< 1 g/dL over 2 weeks
ESA
ADR’s / Contraindications
BLACK BOX WARNING
use the lowest dose sufficient to reduce the need for RBC transfusion
Increased risk of: MI / stroke / VTE / VE / Tumor progression
- *Contraindications**
- *Uncontrolled HTN** / Pure Red Cell Aplasia
- Precautions: (can still start)*
- *Stroke / MI / thromboembolism / Seizures**
ESA
Dose Adjustments
Do NOT dose adjust more frequently than:
Response typically seen:
2-6 weeks
Medicare payment based on:
Hb < 12 g/dL
dose is DIFFERENT for CANCER patients
Monitor Hb:
Weekly / BI-weekly / Monthly
If hemoglobin rises quickly
= >1g/dL in 2 weeks -> may reduce ESA dose by 25%+
if >11g/dL –> reduce or hold dose
If Hb does NOT respond by
>1g/dL in 4 weeks –> increase dose by 25%
response is typically seen over 12 weeks, if no response unlikely to improve
Darbepoetin
ESA - Aranesp
Half Life + Dose
Half-Life
21hr IV // 46hr SC
Dose
0.45 mcg/kg qweekor 0.75mcg/kg q2weeks
For non-dialysis:
0.45 mcg/kg q4 weeks
Methoxy Polyethylene Glycol-Epoetin Beta
ESA - Mircera
Half Life + Dose
Half-Life
134 - 139 H
Dose
0.6 mcg/kg q2 weeks
until Hb stable then double dose qmonth
ONCE EVERY 2 WEEKS
Epoetin Alfa
ESA - Epogen / ProCrit
Half Life + Dose
Half-Life
8.5hr IV // 24hr SC
Dose
50-100 units/kg TIW
THREE TIMES A WEEK
ESA Dose Conversions
Epoetin Alfa = 3x a Week
so, converting to Darbepoetin = Weekly
need to convert accordingly
Also:
Micera is every 2 weeks or every 1 month
Causes for ESA RESISTANCE
**_IRON DEFICIENCY_** #1 cause, should be **iron replete b4 starting ESA**
Inflammation / Infxn
CKD = stage of chronic inflammation
HYPERparathyroidism
Folic Acid + VitB12 Deficiency
Chronic Blood loss / Malnutrtion / Alminum toxicity / Inadequate Dialysis
Cancer + ESA Considerations
INCREASED RISK
of cancer spreading / tumor increase / recurrance
WAIT 5 YEARS to be CANCER FREE
b4 starting ESA
Hepcidin Function
Peptide made in liver that REGULATES:
Intestinal FE absorption / Recycling / Mobilization from hepatic stores
CONTRIBUTES TO ANEMIA in CKD (BAD)
when inflammation / Infection present
- *Hepcidin –> binds to Ferroportin** in macrophages
- INHIBITS Fe Availability*
basis for most:
“anemia of chronic disease”